Table 2.
Discontinuation rates of fremanezumab and subsequent medication changes
| Overall (N = 216) |
Quarterly (n = 29) |
Monthly (n = 187) |
|
|---|---|---|---|
| Discontinuation, n (%) | 216 (100.0) | 29 (100.0) | 187 (100.0) |
| Switching, n (%) | 99 (45.8) | 13 (44.8) | 86 (46.0) |
| Within-class switching | 17 (7.9) | 4 (13.8) | 13 (7.0) |
| Aimovig | 11 (5.1) | 1 (3.4) | 10 (5.3) |
| Emgality | 7 (3.2) | 3 (10.3) | 4 (2.1) |
| Between-class switching | 95 (44.0) | 12 (41.4) | 83 (44.4) |
| Acute medications | 46 (21.3) | 5 (17.2) | 41 (21.9) |
| Triptans | 19 (8.8) | 3 (10.3) | 16 (8.6) |
| Ergot alkaloids | 1 (0.5) | 0 | 1 (0.5) |
| NSAID analgesics | 19 (8.8) | 2 (6.9) | 17 (9.1) |
| Opioid analgesics | 12 (5.6) | 1 (3.4) | 11 (5.9) |
| Miscellaneous | 7 (3.2) | 1 (3.4) | 6 (3.2) |
| Preventive medication | 81 (37.5) | 10 (34.5) | 71 (38.0) |
| Anticonvulsants/antiepileptics | 26 (12.0) | 4 (13.8) | 22 (11.8) |
| Antihypertensive | 19 (8.8) | 1 (3.4) | 18 (9.6) |
| Muscle relaxants | 16 (7.4) | 3 (10.3) | 13 (7.0) |
| Antidepressants | 27 (12.5) | 1 (3.4) | 26 (13.9) |
| Antihistamines | 1 (0.5) | 0 | 1 (0.5) |
| OnabotulinumtoxinA | 7 (3.2) | 0 | 7 (3.7) |
| Reinitiation, n (%) | |||
| Any dose | 28 (13.0) | 2 (6.9) | 26 (13.9) |
| Monthly to quarterly | 1 (0.5) | 0 | 1 (0.5) |
| Quarterly to monthly | 0 | 0 | 0 |
| Permanent discontinuation, n (%) | 103 (47.7) | 14 (48.3) | 89 (47.6) |
NSAID nonsteroidal anti-inflammatory drug